MannKind Corporation (NASDAQ: MNKD)
The stock moved up nearly 11% last week in reaction to a barrage of generally positive articles about the company from financial sites like The Motley Fool, seeking Alpha, and even TheStreet (although Adam Feuerstein is clearly bearish). Still, the stock has strong support from the retail investor audience, and seems to be affected quite strongly by the headlines.
MNKD longs may cause a run-up in the common stock before August 2013, when the company expects to release Phase III top-line data for flagship drug Afrezza. Data is generally expected to be quite good, and a PDUFA date for the Afrezza NDA is expected in mid-2014.
http://www.bio-wire.com/?p=840
